Eisai Co., Ltd.｜A human health care company

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

Learn more

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

Learn more
Human Capital Report 2024

Learn more

Human Capital Report 2024

Learn more
Value Creation Report 2024

Learn more

Value Creation Report 2024

Learn more

News Release
Latest News
Information

September 4, 2025

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 3, 2025

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease
August 30, 2025

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months
LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S.
August 29, 2025

Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to
Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
August 25, 2025

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

August 6, 2025

IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2026 (Webcast)”
August 5, 2025

IR “First Quarter Financial Reports for the Fiscal Year Ending March 31, 2026”
June 19, 2025

About Eisai “Corporate Governance Report”

February 19, 2025

Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”
October 3, 2024

EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024
June 21, 2024

Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
June 3, 2024

The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
April 8, 2024

Eisai Participates in Kakamigahara City’s SDGs Promotion Program through its Activities Including Waste Recycling at the Kawashima Plant

Eisai at a Glance

Eisai Group Worldwide

Eisai's hhc Concept

Innovation

About Eisai

Investors

Sustainability

Sustainability

Making our medicines available to those who need them

32 countries 2.53billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of June 2025)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP